Get a program
One program with its trials and ontology terms. A merged id returns the surviving program.
Authorizations
Use a personal or organization Pav API key from Pav developer settings. Send it as Authorization: Bearer <api_key>.
Path Parameters
Program id.
18342
Response
Successful Response
Program id. Stable; kept when a program is discontinued.
18342
Pav company identifier that owns this program.
412
Company slug, a stable readable identifier.
"pfizer"
Display name of the company that owns this program.
"Pfizer"
Drug or asset name for the program.
"Danuglipron"
active, inactive (known only from trials, all closed) or discontinued. An approved drug stays active after it leaves the company's pipeline page.
"active"
When a discontinued program stopped; null otherwise.
null
How Pav knows of the program: company_pipeline, regulatory_approval (an approved use the pipeline does not list; source_url is the label) or clinical_trial_registry.
company_pipeline, regulatory_approval, clinical_trial_registry "company_pipeline"
Drug id shared by every company's programs of the same product. Null when the program names no product.
5120
Other names of the drug: INN, codes, brands.
Indication the program targets, as published by the company.
"Type 2 Diabetes"
Development phase as published by the company (raw label).
"Phase 2"
Phase in Pav's vocabulary: the developer's phase for this indication, raised to Approved by a US or EU approval that covers it. Without one, the most advanced registered trial of the drug in the indication, then a dated public source. A trial never raises a developer's phase.
"Phase 2"
Drug modality as published by the company (raw label).
"Small molecule"
Modality in Pav's vocabulary; one per drug.
"small_molecule"
Nucleic-acid class: sirna, mrna, sarna, rna_editing, aso, aptamer.
"sirna"
Formats: bispecific (includes tri- and multispecifics), antibody_drug_conjugate, peptide_drug_conjugate, antibody_oligonucleotide_conjugate, antibody_peptide_conjugate.
Molecular target as published. Null when none is published.
"GLP-1R"
Mechanism of action for the asset.
"GLP-1 receptor agonist"
Territory/region the program applies to, when disclosed.
"United States"
Free-text program description, when published.
"Oral GLP-1 receptor agonist for type 2 diabetes and obesity."
Additional program notes from the source.
"Phase 2b dose-finding study ongoing."
Partners the company lists; if none, other companies holding the same drug.
Clinical trials linked to this program.
Ontology (MONDO) terms mapped from the program's indication.
Ontology (NCIT/HGNC) terms mapped from the program's target.
URL of the company page the program was read from.
"https://www.pfizer.com/science/drug-product-pipeline"
When Pav last read the source page (UTC).
"2026-06-19T04:12:00Z"
When the program's latest event happened (a phase change, readout, filing, approval). from/to and sort=last_updated use it.
"2026-09-12T00:00:00Z"